Literature DB >> 31880471

Modeling Clinical Processes to Consent Research Donors of Remnant Biospecimens in an Outpatient Cardiology Clinic.

Stephanie E Soares1, Nicholas R Anderson1,2, Leslie J Solis1, Javier E López3,4.   

Abstract

Introduction: Informed consent for research biospecimen donations is traditionally obtained through a face-to-face interaction with research staff and by signing an Institutional Review Board (IRB)-approved printed form. Electronic signatures (eSign) are routinely used in the electronic medical record (EMR) for the consenting of clinical services after patients review printed documentation. Our goal was to develop an electronic self-consenting workflow that mimicked clinical services. Specifically, we tested a research consent process for the biobanking of remnant clinical samples that relies solely on clinical resources in a busy outpatient practice. Materials and
Methods: The Biorepositories Core Resource (BCR) unit initiated a new enterprise-wide biobanking infrastructure for consenting patients, termed Biospecimen Use for Research-Related Investigations and Translational Objectives (BURRITO). BURRITO is modeled after an established clinical process called Terms and Conditions of Service (TACOS). The TACOS requires patients to annually review printed documentation and self-consent electronically for clinical services. BURRITO also requires patients to review printed documentation and self-consent with eSign to opt-in for remnant biospecimen banking, but patients must complete this process only once. We captured eSign for consents directly into the EMR without research staff.
Results: Patients reviewed the IRB-approved documents and self-consented during their cardiology clinic visit. At checkout, their participation preferences were electronically documented by clinic staff. During a 6-month period, 123 patients agreed to donate. After a review of process, a second 3-month period identified 202 patients agreeing to donate. BURRITO did not require face-to-face interactions with research staff, used a "no-paper" eSign for consent, and created discrete fields in the clinical EMR of the patient's preference. Conclusions: BURRITO electronically documents informed consent using an EMR functionality and the least amount of clinical and research resources. Our results show promise for developing institutionally adopted processes, which could leverage existing clinical workflows for universal research consenting and scalability.

Entities:  

Keywords:  biological specimen; electronic health records; informed consent; quality improvement

Mesh:

Year:  2019        PMID: 31880471      PMCID: PMC7185316          DOI: 10.1089/bio.2019.0023

Source DB:  PubMed          Journal:  Biopreserv Biobank        ISSN: 1947-5543            Impact factor:   2.300


  15 in total

1.  Sustainability of Biobanks in the Future.

Authors:  Yvonne G De Souza
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

2.  Finding ways to improve the use of biobanks.

Authors:  Angelo Paradiso; Mats Hansson
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Development of a large-scale de-identified DNA biobank to enable personalized medicine.

Authors:  D M Roden; J M Pulley; M A Basford; G R Bernard; E W Clayton; J R Balser; D R Masys
Journal:  Clin Pharmacol Ther       Date:  2008-05-21       Impact factor: 6.875

4.  Traditional and electronic informed consent for biobanking: a survey of U.S. biobanks.

Authors:  Christian M Simon; David W Klein; Helen A Schartz
Journal:  Biopreserv Biobank       Date:  2014-12       Impact factor: 2.300

5.  Biobanking sustainability--experiences of the Australian Breast Cancer Tissue Bank (ABCTB).

Authors:  Jane E Carpenter; Christine L Clarke
Journal:  Biopreserv Biobank       Date:  2014-12       Impact factor: 2.300

6.  The Common Rule, Updated.

Authors:  Jerry Menikoff; Julie Kaneshiro; Ivor Pritchard
Journal:  N Engl J Med       Date:  2017-01-19       Impact factor: 91.245

7.  Principles of human subjects protections applied in an opt-out, de-identified biobank.

Authors:  Jill Pulley; Ellen Clayton; Gordon R Bernard; Dan M Roden; Daniel R Masys
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

Review 8.  A template for broad consent in biobank research. Results and explanation of an evidence and consensus-based development process.

Authors:  D Strech; S Bein; M Brumhard; W Eisenmenger; C Glinicke; T Herbst; R Jahns; S von Kielmansegg; G Schmidt; J Taupitz; H D Tröger
Journal:  Eur J Med Genet       Date:  2016-04-26       Impact factor: 2.708

Review 9.  Human biological sample biobanking to support tissue biomarkers in pharmaceutical research and development.

Authors:  Christopher Womack; S Rachel Mager
Journal:  Methods       Date:  2014-01-30       Impact factor: 3.608

10.  Biobanks containing clinical specimens: defining characteristics, policies, and practices.

Authors:  Teresa Edwards; R Jean Cadigan; James P Evans; Gail E Henderson
Journal:  Clin Biochem       Date:  2013-12-15       Impact factor: 3.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.